Pharmaceutical Letrozole Intermediates Raw Femara Steroids Powder for Muscle Growth CasNO.112809-51-5

Letrozole is used to treat postmenopausal women with hormone receptor positive early breast cancer or who have been treated with tamoxifen. It also is approved for initial or second-line treatment of postmenopausal women with hormone-sensitive or advanced breast cancer. Letrozole is used to treat certain types of breast cancer in women who have already stopped menstruating. It is also used for women who have already had other cancer treatments.

Letrozole, an aromatase inhibitor, has been demonstrated to be effective as an ovulation induction and controlled ovarian hyperstimulation agent. However, dose administration has generally been limited to 5 days at 2.5 to 7.5 mg daily. We undertook a retrospective review of over 900 treatment cycles using letrozole in doses as high as 12.5 mg per day. Results indicate that such doses do indeed offer benefit to patients; in that there is increased follicular growth and a higher number of predicted ovulations with higher doses of the drug. However, increasing doses does not produce a detrimental effect upon endometrial thickness. High-dose letrozole may be of value in women who fail to respond adequately to lower doses. Furthermore, randomized trials are needed to determine whether high-dose letrozole might actually be optimal as a starting dose for certain treatment groups.

Letrozole can be used in patients working on getting pregnant with PCOS (or polycystic ovary syndrome) who have irregular or absent period. Letrozole can be used as an alternative in women who develop a thin uterine lining on clomiphene citrate. Unlike clomiphene citrate, with letrozole there is no blockage of estrogen receptors and the uterine lining and cervical mucus are not affected.

Letrozole is approved by the united states food and drug administration (fda) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Letrozole is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.